Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States

被引:16
作者
Fereidan-Esfahani, Mahboubeh [1 ,2 ]
Decker, Paul A. [3 ]
Passow, Jeanette E. Eckel [3 ]
Lucchinetti, Claudia F. [1 ,2 ]
Flanagan, Eoin Patrick [2 ]
Tobin, William Oliver [1 ,2 ]
机构
[1] Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Ctr Multiple Sclerosis & Autoimmune Neurol, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA
关键词
demyelination; incidences; multiple sclerosis; Olmsted County; MN; tumefactive; MULTIPLE-SCLEROSIS; LESIONS; DIAGNOSIS; FEATURES; EPIDEMIOLOGY; SPECTRUM; CRITERIA; BRAIN; MRI;
D O I
10.1111/ene.15182
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose Tumefactive demyelination (TD) presents with large inflammatory lesions mimicking tumors or other space-occupying lesions. Limited epidemiological, clinical and radiological data exist for TD. We aimed to report the incidence rate, and clinical and radiological features of TD in Olmsted County, Minnesota. Methods We retrospectively reviewed patients with central nervous system inflammatory demyelination-related diagnostic codes (January 1, 1998 to December 31, 2018) in the Rochester Epidemiology Project database, and adjusted incidence rates by age and sex to the 2010 US total population. We used the Expanded Disability Status Scale (EDSS) to assess outcomes (index attack and last follow-up). Results Of 792 multiple sclerosis (MS) patients, 15 (eight males, seven females) had tumefactive MS, representing 1.9% of the MS population. The median (range) age at attack onset was 34.2 (2-61) years. Tumefactive lesion was the first clinical MS attack in 8/16 patients. Cerebrospinal fluid oligoclonal bands (OCBs) were present in 8/12 patients and 11/16 patients met the Barkhof criteria for dissemination in space. Most patients remained fully ambulatory (EDSS score <= 4 in 13/16 patients [81%]) after a median (range) follow-up duration of 10.5 (1-20.5) years. Age-adjusted annual incidence rates were 0.46/100,000 (95% confidence interval [CI] 0.12-0.81) for female patients, 0.66/100,000 (95% CI 0.23-1.02) for male patients, and 0.56/100,000 [95% CI 0.28-0.83] overall. When age- and sex-adjusted to the 2010 US total population, the overall annual incidence rate was 0.57 (95% CI 0.28-0.84). Despite aggressive clinical presentation at disease onset, most patients remained fully ambulatory (EDSS score <= 4 in 13/16 patients) with a relapsing-remitting course. Conclusions Although incidence is rare, TD should be suspected in patients presenting with subacutely progressive neurological deficits associated with magnetic resonance imaging findings of ring enhancement, apparent diffusion coefficient restriction, and OCB on spinal fluid analysis.
引用
收藏
页码:782 / 789
页数:8
相关论文
共 31 条
[1]   Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study [J].
Altintas, A. ;
Petek, B. ;
Isik, N. ;
Terzi, M. ;
Bolukbasi, F. ;
Tavsanli, M. ;
Saip, S. ;
Boz, C. ;
Aydin, T. ;
Arici-Duz, O. ;
Ozer, F. ;
Siva, A. .
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (10) :1448-1453
[2]   Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients [J].
Balloy, G. ;
Pelletier, J. ;
Suchet, L. ;
Lebrun, C. ;
Cohen, M. ;
Vermersch, P. ;
Zephir, H. ;
Duhin, E. ;
Gout, O. ;
Deschamps, R. ;
Le Page, E. ;
Edan, G. ;
Labauge, P. ;
Carra Dallieres, C. ;
Rumbach, L. ;
Berger, E. ;
Lejeune, P. ;
Devos, P. ;
N'Kendjuo, J. -B. ;
Coustans, M. ;
Auffray-Calvier, E. ;
Daumas-Duport, B. ;
Michel, L. ;
Lefrere, F. ;
Laplaud, D. A. ;
Brosset, C. ;
Derkinderen, P. ;
de Seze, J. ;
Wiertlewski, S. .
JOURNAL OF NEUROLOGY, 2018, 265 (10) :2251-2259
[3]   Encephalitis periaxialis concentrica [J].
Balo, J .
ARCHIVES OF NEUROLOGY AND PSYCHIATRY, 1928, 19 (02) :242-264
[4]   Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments [J].
Brod, Staley A. ;
Lindsey, J. William ;
Nelson, Flavia .
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2019, 5 (02)
[5]   Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders [J].
Frederick, Meredith C. ;
Cameron, Michelle H. .
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2016, 16 (03) :1-7
[6]   Atypical inflammatory demyelinating syndromes of the CNS [J].
Hardy, Todd A. ;
Reddel, Stephen W. ;
Barnett, Michael H. ;
Palace, Jacqueline ;
Lucchinetti, Claudia F. ;
Weinshenker, Brian G. .
LANCET NEUROLOGY, 2016, 15 (09) :967-981
[7]   MOG encephalomyelitis: international recommendations on diagnosis and antibody testing [J].
Jarius, S. ;
Paul, F. ;
Aktas, O. ;
Asgari, N. ;
Dale, R. C. ;
de Seze, J. ;
Franciotta, D. ;
Fujihara, K. ;
Jacob, A. ;
Kim, H. J. ;
Kleiter, I. ;
Kuempfel, T. ;
Levy, M. ;
Palace, J. ;
Ruprecht, K. ;
Saiz, A. ;
Trebst, C. ;
Weinshenker, B. G. ;
Wildemann, B. .
JOURNAL OF NEUROINFLAMMATION, 2018, 15
[8]   Tumefactive demyelinating lesions as a first clinical event: Clinical, imaging, and follow-up observations [J].
Jeong, In Hye ;
Kim, Su-Hyun ;
Hyun, Jae-Won ;
Joung, AeRan ;
Cho, Hyo-Jin ;
Kim, Ho Jin .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 358 (1-2) :118-124
[9]   FULMINANT MONOPHASIC MULTIPLE-SCLEROSIS, MARBURGS TYPE [J].
JOHNSON, MD ;
LAVIN, P ;
WHETSELL, WO .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (10) :918-921
[10]   Clinical and Radiologic Features, Pathology, and Treatment of Balo Concentric Sclerosis [J].
Jolliffe, Evan A. ;
Guo, Yong ;
Hardy, Todd A. ;
Morris, P. Pearse ;
Flanagan, Eoin P. ;
Lucchinetti, Claudia F. ;
Tobin, W. Oliver .
NEUROLOGY, 2021, 97 (04) :E414-E422